Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC | Institution(s) | Investigator(s) | Location(s) | Year Awarded |
---|---|---|---|---|---|---|---|---|
1R61DA059168-01
Show Summary |
The Use of Novel Linked Databases to Reduce Postoperative Opioid Use Among Patients Undergoing Inpatient Surgery | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | STANDFORD UNIVERSITY | SUN, ERIC (contact); COLQUHOUN, DOUGLAS ALASTAIR | Stanford, CA | 2023 |
NOFO Title: HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional)
NOFO Number: RFA-DA-23-057 Summary: Older adults make up more than half of all surgical patients in the United States, putting them at risk for a range of harmful outcomes including misusing opioids, developing opioid use disorder (OUD), opioid overdose, and surgical complications. This project seeks to understand whether pre-surgery interventions can prevent harmful opioid-related outcomes. The research will combine data from a registry of electronic health records and from Medicare claims data to learn about the relationship between these interventions and opioid-related outcomes including persistent opioid use, OUD, and other harmful outcomes. |
||||||||
1R43TR004743-01
Show Summary |
The Pain in a Dish Assay (PIDA): A High Throughput System Featuring Human Stem Cell-Derived Nociceptors and Dorsal Horn Neurons to Test Compounds for Analgesic Activity | Cross-Cutting Research | Small Business Programs | NCATS | VALA SCIENCES, INC. | MCDONOUGH, PATRICK M | San Diego, CA | 2023 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-23-006 Summary: This project will develop PIDA, which will allow researchers to measure the activity of pain-sensitive human neurons in response to pain stimuli and potential pain treatments. The tool will use automated digital microscopes in the absence or presence of a potential pain medication. Since this tool contains human neurons, it may be more effective at predicting the efficacy of potential pain drugs in human patients than the animal models that are currently used. |
||||||||
1R44DA058531-01
Show Summary |
BoostPrime, A Novel Digital Therapeutic for Craving Mitigation in Opioid Use Disorder | Cross-Cutting Research | Small Business Programs | NIDA | NXTECH, INC. | PATEL, SALIL | Patchogue, NY | 2023 |
NOFO Title: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-021 Summary: Cravings and impulsivity are key contributors that lead people to return to opioid misuse, but are not addressed by currently available treatments and tools. This project will develop and validate BoostPrime, a customized digital therapeutic software tool that delivers novel cognitive training exercises. The tool aims to help address cravings and strengthen momentary self-control for people with opioid use disorder by incorporating. |
||||||||
1R43HL167661-01A1
Show Summary |
Improving Analgesic Effectiveness and Safety with Proactive Precision Pain Management in Thoracic Surgical Patients with Lung Lesions | Cross-Cutting Research | Small Business Programs | NHLBI | OPALGENIX, INC. | PLUMP, STEVEN R (contact); SADHASIVAM, SENTHILKUMAR | Carmel, IN | 2023 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 Summary: Thoracic (chest) surgeries often cause both short-term (acute) and long-term (chronic) pain and long-term opioid use. Unique genetic and clinical risk factors affect individual responses to surgical pain and pain medications. Current trial-and-error approaches to managing post-surgical pain and opioid prescribing are not ideal. This project will develop predictive software within a medical device that takes into account an individual’s genetic and clinical information to predict the likelihood of chronic pain following thoracic surgery. |
||||||||
1R61DA057629-01A1
Show Summary |
Chicago Data-driven OUD Screening, Engagement, Treatment and Planning (C-DOSETaP) System | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | UNIVERSITY OF ILLINOIS AT CHICAGO | KARNIK, NIRANJAN | Chicago, IL | 2023 |
NOFO Title: HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional)
NOFO Number: RFA-DA-23-057 Summary: Health services for the treatment of opioid use disorder (OUD) are fragmented in west Chicago, an epicenter for overdose deaths. This project will develop a data-driven opioid response plan involving key partners. These include local health departments, community organizations, health care systems, and people with lived experience. The research will develop a digital screening tool for OUD that can be used in hospitals and their emergency departments. The tool will be built from machine learning of data from electronic health records, the prescription drug monitoring program, and patient-reported measures. The research will test the value of the screening tool for connecting people to treatment and preventing fatal overdoses mortality in local neighborhoods. |
||||||||
1DP2HD112176-01
Show Summary |
Identifying Plasma Proteomic Profiles of Chronic Pain Development in Endometriosis From Adolescence to Adulthood | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NICHD | BRIGHAM AND WOMEN'S HOSPITAL | SASAMOTO, NAOKO | Boston, MA | 2023 |
NOFO Title: Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
NOFO Number: RFA-TR-22-013 Summary: Endometriosis is a gynecologic disorder characterized by severe pelvic pain, affecting 10% of reproductive aged women and adolescents worldwide. These individuals are at an increased risk for chronic opioid use, dependence, and overdose. Adolescents and young adults in particular are understudied in endometriosis research. This project will conduct a longitudinal study of adolescent endometriosis. The research will identify novel biomarkers and biological pathways involved in the transition of acute to chronic pain. The research aims to improve non-surgical endometriosis diagnosis, risk, and treatment. |
||||||||
1R43DA058614-01
Show Summary |
Combination Therapeutic for Chronic Opioid Use Disorder Relapse | Cross-Cutting Research | Small Business Programs | NIDA | APHIOS CORPORATION | CASTOR, TREVOR P | Woburn, MA | 2023 |
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-22-176 Summary: Side effects from taking the opioid receptor blocker naltrexone make it difficult for patients to adhere to treatment with this medication for opioid use disorder. Cannabidiol (CBD), a bioactive ingredient of cannabis, is not an opioid and is non-psychoactive. Previous research shows that CBD blocks opioid-seeking behaviors, craving, and withdrawal. This project will develop tiny particles containing CBD and low-dose naltrexone. The research will determine if this combined version of CBD and naltrexone helps people stay in treatment and prevents relapse without problematic side effects. |
||||||||
1K01DA058750-01
Show Summary |
Leveraging mHealth to Increase Health Equity Among Black Individuals with OUD and Commonly Occurring Mental Health Disorders | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NIDA | WASHINGTON UNIVERSITY | SZLYK, HANNAH | Saint Louis, MO | 2023 |
NOFO Title: HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)
NOFO Number: PAS-22-206 Summary: This project provides protected time for training and research activities that are required for an independent scientific career in the development, testing, and implementation of cutting-edge digital therapies and tools (such as smartphone apps and other web-based resources) that can promote health equity in treatment of opioid use disorder (OUD). The research will adapt and test digital overdose prevention and recovery support interventions for Black Americans with co-occurring OUD and mental illness. |
||||||||
1R44AR083337-01
Show Summary |
Development of a Regional Anesthesia Guidance System to Increase Patient Access to Opioid-Sparing Analgesia for Hip Fracture Pain | Cross-Cutting Research | Small Business Programs | NIAMS | RIVANNA MEDICAL, INC. | MAULDIN, FRANK WILLIAM | Charlottesville, VA | 2023 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-23-006 Summary: Every year, more than 330,000 Americans are hospitalized for hip fractures. Rapid surgical intervention and pain treatment is critical to recover mobility and reduce other health complications. Ultrasound-guided regional anesthesia techniques are an effective alternative to opioid medication, but require specialized training for use in the emergency department. This project will develop and validate an easy-to-use ultrasound-based regional anesthesia guidance system, to ultimately improve access to non-opioid-pain treatment for hip fracture pain. |
||||||||
2R44DA048689-02
Show Summary |
Beacon-OUD: Behavioral Economic Screening Tool of Opioid Use Disorder (OUD) for Use in Clinical Practice | Cross-Cutting Research | Small Business Programs | NIDA | BEAM DIAGNOSTICS, INC. | SNIDER, SARAH EMILY | Roanoke, VA | 2023 |
NOFO Title: PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-21-259 Summary: Current clinical screening measures for opioid misuse are underused and susceptible to bias. This project will develop Beacon-OUD, a digital opioid misuse assessment. The tool generates an automated, standardized score, preventing potential judgements related to patient’s status and circumstances, limiting stigma. The research will further advance Beacon-OUD into a commercial product for use both as a stand-alone tool and as an electronic health record-integrated solution to encourage objective opioid misuse screening in large health care systems. |
||||||||
2R44MD015912-03
Show Summary |
Clinical Optimization of Ultrasonic Drug Delivery Technologies for Underserved Minority U.S. Veterans in Chronic Pain | Cross-Cutting Research | Small Business Programs | NIMHD | ZETROZ SYSTEMS, LLC | LEWIS, GEORGE KENNETH | Trumbull, CT | 2023 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)
NOFO Number: RFA-NS-20-010 Summary: Osteoarthritis is one of the most common joint diseases affecting Americans. Osteoarthritis is particularly high among veterans with a service-related disability. This project will develop and refine a wireless ultrasound device that increases the penetration of over-the-counter pain medications into the body, which is expected to reduce pain. The research will conduct safety and clinical testing toward commercializing this technology. |
||||||||
1R61DA059169-01
Show Summary |
Leveraging Data to Action: Accelerating Emergency Department OUD Care by Improving Data Access and Infrastructure | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | YALE UNIVERSITY | VENKATESH, ARJUN KRISHNA (contact); HAWK, KATHRYN; TAYLOR, RICHARD ANDREW | New Haven, CO | 2023 |
NOFO Title: HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional)
NOFO Number: RFA-DA-23-057 Summary: Emergency departments (EDs) are key settings for identifying and treating opioid use disorder (OUD), but EDs are underused for this purpose. This project aims to develop a data system that automates and integrates electronic health record and administrative data from EDs into the Clinical Emergency Department Registry, partnering with the American College of Emergency Physicians. The research will assess the digital readiness of ED systems before developing and deploying the enhanced ED OUD data infrastructure. This research aims to guide near-real time hospital quality improvement initiatives, toward development of a web-based, near-real time dashboard that can be used in EDs across the country. |
||||||||
1R41NS132625-01A1
Show Summary |
Opioid-Sparing Non-Surgical, Bioresorbable Nerve Stimulator for Pain Relief | Cross-Cutting Research | Small Business Programs | NINDS | VANISH THERAPEUTICS INC. | CUI, XINYAN TRACY | Mars, PA | 2023 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-23-007 Summary: Nerve stimulators are devices surgically implanted near a peripheral nerve or on the spinal cord that use electrical signals to reduce the perception of pain. Although these devices can provide effective pain relief to patients, many have high complication rates, resulting from the wire moving, breaking, not working, or the implantable battery pack or permanent wire causing new pain. This project will support the development and animal testing of a peripheral nerve stimulator to treat chronic pain which can be implanted without surgery. Once injected, the device will provide pain relief through electrical stimulation and then be safely degraded and resorbed by the body. |
||||||||
1R44DA058474-01
Show Summary |
Development of the OpiAID Strength Band Platform | Cross-Cutting Research | Small Business Programs | NIDA | OPIAID, INC. | REESER, DAVID (contact); MACQUEEN, DAVID ALDERSON; WASHINGTON, WENDY DONLIN | Wilmington, NC | 2023 |
NOFO Title: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-23-021 Summary: Although medications for opioid use disorder are effective and available, providers currently lack methods to monitor patients and thus inform improved dosing. This project will develop Strength Band Platform, an innovative artificial intelligence-based digital platform. The wearable device will collect patient physiological characteristics to detect relapse and withdrawal during treatment with medications for opioid use disorder in real-world settings. |
||||||||
3R01DA057630-01S1
Show Summary |
Predicting Fatal and Non-Fatal Overdose in Los Angeles County with Rapid Overdose Surveillance Dashboard to Target Street-Based Addiction Treatment and Harm Reduction Services | Cross-Cutting Research | Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research | NIDA | UNIVERSITY OF CALIFORNIA LOS ANGELES | SHOVER, CHELSEA LEIGH (contact); GOODMAN, DAVID | Los Angeles, CA | 2023 |
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
NOFO Number: PA-21-071 Summary: The International Classification of Diseases 10th revision codes are insufficient to accurately identify individuals who use opioids and stimulants together. This project will search already collected electronic health record data using a computer program to identify people with polysubstance use and determine what health care they receive. The research will improve understanding of polysubstance use in a region of Los Angeles, California, with very high rates of overdoses involving fentanyl and stimulants. |
||||||||
1R44DA059302-01
Show Summary |
Development of an Opioid Sparing Therapeutic to Minimize Opioid Use Disorder and Tolerance in the Treatment of Pain | Cross-Cutting Research | Small Business Programs | NIDA | AMALGENT THERAPEUTICS, LLC | MEYN, MALCOLM A | Greenville, NC | 2023 |
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-22-176 Summary: Managing the risks and benefits of opioid medications can be difficult. Although prescription opioids alleviate pain for some patients, serious adverse effects include opioid use disorder. There is a critical, unmet need for new technologies that significantly minimize the opioid doses needed for effective relief from moderate to severe pain. This project will develop a novel combination treatment containing a small amount of morphine along with pramipexole, a drug approved by the U.S. Food and Drug Administration for Parkinson’s disease and restless legs syndrome that reduces the reward-seeking behavior associated with opioids. The research will conduct safety studies to enable testing in human research participants. |
||||||||
1R44NS125745-01A1
Show Summary |
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P) | Cross-Cutting Research | Small Business Programs | NINDS | EVON MEDICS, LLC | NWAOKOBIA, CHARLES CHIEDU (contact); NWULIA, EVARISTUS A | Elkridge, MD | 2022 |
NOFO Title: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)
NOFO Number: RFA-NS-20-010 Summary: Research shows that individuals with chronic pain may experience brain changes that contribute to anxiety, depression, and cognitive impairment. This project will test a user-friendly, home-based device to treat chronic pain. The device stimulates the brain through olfactory training: repetitive daily stimulation with specific smells. The research will optimize a treatment approach and test the device in a clinical study. |
||||||||
3UH3AR076729-02S1
Show Summary |
The Spine Phenome Project: Enhancing Patient Diversity | Cross-Cutting Research | Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research | NIAMS | OHIO STATE UNIVERSITY | MARRAS, WILLIAM STEVEN | Columbus, OH | 2022 |
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies
NOFO Number: NOT-NS-22-066 Summary: Chronic pain is a debilitating medical condition that affects roughly 50 million people in the United States. Current diagnostics and treatments rely primarily on subjective metrics and do not target the unique biological, psychological, and social factors that contribute to an individual’s pain. This project is part of the NIH Back Pain Consortium (BACPAC) program, a patient-centered effort to address the need for effective and personalized therapies for chronic low back pain. This research will enhance patient diversity within the BACPAC research participant population. |
||||||||
1R43CA268700-01A1
Show Summary |
Pre-clinical Validation of Phase II Peptide LRP-1 Agonist to Treat and Prevent Chemotherapy Induced Peripheral Neuropathy | Cross-Cutting Research | Small Business Programs | NCI | SERPIN PHARMA, LLC | GELBER, COHAVA (contact); CAMPANA, WENDY M | Manassas, VA | 2022 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 Summary: Some chemotherapy treatments damage nerves outside the brain and spinal cord. This condition, chemotherapy-induced peripheral neuropathy, involves tingling, burning, weakness, or numbness in hands and/or feet and affects nearly 70% of cancer patients receiving chemotherapy. Common pain medications, including opioids, can relieve pain for short intervals but are not suitable for long-term therapy. This project will develop and test a new type of treatment (reduced size cyclic analogs) for this condition. The research will evaluate the ability of this therapy to reduce inflammation and pain, as well as to repair nerve damage. |
||||||||
1R44CA271904-01A1
Show Summary |
Novel Biologic to Treat Chemotherapy-Induced Neuropathic Pain | Cross-Cutting Research | Small Business Programs | NCI | RAFT PHARMACEUTICALS, LLC | KOGAN, YAKOV | San Diego, CA | 2022 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011 Summary: Some chemotherapy treatments damage nerves outside the brain and spinal cord. This condition, chemotherapy-induced peripheral neuropathy, involves tingling, burning, weakness, or numbness in hands and/or feet and affects nearly 70% of cancer patients receiving chemotherapy. Common pain medications, including opioids, can relieve pain for short intervals but are not suitable for long-term therapy. This project will conduct studies to investigate the safety and tolerability of a novel strategy to treat neuropathic pain: modifying the activity of the dorsal root ganglia, which are nerve cells in the spinal cord that communicate pain signals to and from the brain. |
||||||||
1R21CA277849-01
Show Summary |
The Effects of Hydrocodone Rescheduling on Pain Management of Older Lung Cancer Patients | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NCI | PENNSYLVANIA STATE UNIV HERSHEY MED CTR | SHEN, CHA | Hershey, PA | 2022 |
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Managementin Humans (R21 Clinical Trials Not Allowed)
NOFO Number: RFA-DE-22-011 Summary: Pain is common, complex, and debilitating in many cancer patients. Although adequate pain management can significantly improve health-related quality of life for these individuals, substantial disparities limit care access, especially among underserved populations. After the 2014 Drug Enforcement Agency policy that raised the risk potential of the opioid hydrocodone (from Schedule III to Schedule II), few studies examined the impact of this policy on pain management strategies and outcomes among cancer patients. This project will use national cancer registry data linked with Medicare claims to assess the change in opioid and non-opioid medication use among older lung cancer patients before and after this policy change. By focusing on older racial/ethnic minority groups dually eligible for both Medicare and Medicaid, the research will also examine disparities in the use of medications for pain management and service use consistent with inadequate pain management. |
||||||||
1R41AR080620-01A1
Show Summary |
Injectable Ice Slurry Cooling Technology for Treatment of Postoperative Pain | Cross-Cutting Research | Small Business Programs | NIAMS | BRIXTON BIOSCIENCES, INC. | SIDOTI, CHARLES | Cambridge, MA | 2022 |
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-009 Summary: More than 700,000 total knee replacement surgeries are performed each year in the United States to relieve joint pain in patients with end-stage osteoarthritis or rheumatic arthritis. However, many patients still experience significant pain after this procedure, calling for additional long-lasting, drug-free pain management strategies. This project will develop and test a commercial prototype device for persistent knee pain after total knee replacement. The injection-based method freezes peripheral nerves to reduce pain sensation. |
||||||||
3UH3AR076387-02S2
Show Summary |
Fibromyalgia TENS in Physical Therapy Study (TIPS): An Embedded Pragmatic Clinical Trial | Cross-Cutting Research | Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research | NIAMS | UNIVERSITY OF IOWA | SLUKA, KATHLEEN A | Iowa City, IA | 2022 |
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies
NOFO Number: NOT-NS-22-066 Summary: Fibromyalgia is a chronic pain condition characterized by widespread musculoskeletal pain, tenderness, stiffness, fatigue, and sleep disturbance. The FAST trial (Fibromyalgia Activity Study with transcutaneous electrical nerve stimulation [TENS]) was the first study to conclusively demonstrate the clinical value of TENS for treating musculoskeletal pain. While physical therapists are trained in the use of TENS, it is underused in clinical practice. This project will test TENS in fibromyalgia patients receiving physical therapy in a real-world physical therapy practice setting. This research will determine if adding TENS to physical therapy reduces pain, increases adherence to physical therapy and allows fibromyalgia patients to reach their self-defined functional goals with less use of medication. |
||||||||
1R21AG082344-01
Show Summary |
Using Secondary Analyses to Test Novel Pathways Linking Family Stress and Pain Incidence and Persistence Among African Americans | Cross-Cutting Research | Leveraging Existing and Real-Time Opioid and Pain Management Data | NIA | UT SOUTHWESTERN MEDICAL CENTER | WOODS, SARAH B | Dallas, TX | 2022 |
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Managementin Humans (R21 Clinical Trials Not Allowed)
NOFO Number: RFA-DE-22-011 Summary: Chronic pain is a persistent source of disability and reduced quality of life for aging adults. Chronic pain-related outcomes are disproportionately worse for aging African Americans, who report greater pain severity and worse pain-related disability compared to White peers. A significant pain risk factor for African Americans is chronic stress (including family-related stress), which is worsened by structural inequities that affect this population. Although many African Americans identify family support as critical for pain self-management, this influence has not been studied thoroughly. This project will study how pain conditions develop and persist for aging African Americans by analyzing existing data from African American participants in two large aging studies: Midlife in the U.S. (721 participants) and the Health and Retirement Study (2,698 participants). The research aims to determine how family emotional climate affects pain risk, taking into account structural factors like discrimination, socioeconomic disparity, and the influence of various neighborhood settings. |
||||||||
1U24DA057650-01
Show Summary |
HEAL Data2Action Modeling and Economic Resource Center | Cross-Cutting Research | Translating Data 2 Action to Prevent Overdose | NIDA | WEILL MEDICAL COLL OF CORNELL UNIV | SCHACKMAN, BRUCE R (contact); LINAS, BENJAMIN P; MCCOLLISTER, KATHRYN E | New York, NY | 2022 |
NOFO Title: HEAL Initiative: HEAL Data2Action Modeling and Economic Resource Center (U24 Clinical Trial Optional)
NOFO Number: RFA-DA-22-049 Summary: This project creates the HEAL Data2Action Modeling and Economic Resource Center that will conduct research as well as support the HEAL Data2Action Innovation Projects with expertise and consultation about simulation modeling and economic evaluation methods. The consultation service will advise on how to select and use various research methods, including economic evaluation, simulation modeling, advanced statistical analysis, behavioral economics, treatment program organization research, and cost analysis. The center will use a dynamic simulation model of opioid use disorder to enhance data-driven decision making. The center will also provide online training resources, tools, and other resources to assess a variety of economic aspects related to the HEAL Data2Action Innovation Projects. |